Upcoming Investor Conferences for Revolution Medicines
Revolution Medicines, Inc. (NASDAQ: RVMD) has announced exciting news for investors and stakeholders alike. The company is actively involved in three key investor conferences that will showcase their advancements in the field of oncology and provide insights into their innovative targeted therapies.
Details of the Participation
The participation details for the conferences are as follows:
TD Cowen Annual Healthcare Conference
Revolution Medicines' CEO, Mark A. Goldsmith, M.D., Ph.D., will lead a fireside chat on Monday, March 3 at 1:50 p.m. ET. This conference presents a great opportunity to explore the company’s pipeline and strategic plans.
Barclays Global Healthcare Conference
Following this, on Tuesday, March 11 at 8:00 a.m. ET, Dr. Goldsmith will present at the Barclays 27th Annual Global Healthcare Conference. Attendees can expect discussions surrounding the firm’s commitments and novel approaches to cancer treatment.
2025 Leerink Partners Global Healthcare Conference
The third conference where Revolution Medicines will be featured is the 2025 Leerink Partners Global Healthcare Conference. This session will take place on Wednesday, March 12 at 2:20 p.m. ET, where the company will discuss its milestones and strategic vision.
How to Access the Webcasts
For those interested in following these discussions live, the company will provide access to webcasts from each conference. After the events, replays will be made available for at least 14 days. This is a valuable chance for investors to stay informed about the latest developments in oncology and Revolution Medicines' contributions to the field.
About Revolution Medicines, Inc.
As a late-stage clinical oncology firm, Revolution Medicines focuses on creating novel targeted therapies for patients facing RAS-addicted cancers. The company champions a rigorous R&D pipeline featuring RAS(ON) inhibitors like daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805). These drugs are at various stages of clinical development, striving to provide critical treatment options for patients dealing with difficult oncogenic variants.
In addition to these notable compounds, Revolution Medicines is exploring other selective mutant inhibitors that promise to expand their effectiveness against resistant cancer types, showcasing their commitment to combating serious health challenges.
Contact Information
For further inquiries or media-related questions, Revolution Medicines can be reached through:
Email: media@revmed.com
Email: investors@revmed.com
Frequently Asked Questions
1. What is Revolution Medicines known for?
Revolution Medicines is recognized for developing targeted therapies for RAS-addicted cancers.
2. Who will be presenting at the investor conferences?
Mark A. Goldsmith, M.D., Ph.D., the CEO, will be presenting at all three upcoming conferences.
3. How can I access the investor calls?
Live webcasts will be available through the company’s website and can be accessed for 14 days post-event as recorded sessions.
4. What are RAS(ON) inhibitors?
RAS(ON) inhibitors are a class of drugs being developed by Revolution Medicines to target and suppress specific oncogenic variants of the RAS proteins in cancer cells.
5. How can I learn more about Revolution Medicines and their pipeline?
For more information, visit their official website or reach out via provided email contacts.